NASDAQ:AVXL Anavex Life Sciences Q2 2026 Earnings Report $2.91 -0.17 (-5.52%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$2.91 0.00 (0.00%) As of 05/15/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Anavex Life Sciences EPS ResultsActual EPSN/AConsensus EPS -$0.07Beat/MissN/AOne Year Ago EPSN/AAnavex Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnavex Life Sciences Announcement DetailsQuarterQ2 2026Date5/19/2026TimeBefore Market OpensConference Call DateTuesday, May 19, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Anavex Life Sciences Earnings HeadlinesAnavex Life Sciences Announces COO Departure Amid RestructuringMay 15 at 6:30 PM | tipranks.comAnavex Life Sciences (NASDAQ:AVXL) Stock Price Passes Below 50-Day Moving Average - Should You Sell?May 13 at 4:59 AM | americanbankingnews.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 16 at 1:00 AM | Porter & Company (Ad)Anavex Life Sciences (AVXL) to Release Earnings on MondayMay 10, 2026 | americanbankingnews.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Receives Consensus Rating of "Hold" from BrokeragesMay 9, 2026 | americanbankingnews.comCEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in FocusMay 6, 2026 | finance.yahoo.comSee More Anavex Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email. Email Address About Anavex Life SciencesAnavex Life Sciences (NASDAQ:AVXL) Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need. The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia. Anavex also holds ANAVEX3‐71, a muscarinic receptor agonist, in its pipeline for Rett syndrome and other developmental disorders. Through these programs, the company aims to demonstrate disease‐modifying effects by addressing underlying cellular dysfunction rather than solely managing symptoms. Since its founding in 2012, Anavex has completed multiple Phase I and Phase II trials in North America and Europe, collaborating with academic research centers and contract research organizations to support its clinical development. The company has established manufacturing partnerships to ensure supply of clinical‐grade API and plans to expand its trial network into additional regions as programs advance. Christopher U. Missling serves as President and CEO, bringing more than two decades of experience in pharmaceutical research and development. Under his leadership, Anavex continues to explore strategic collaborations and funding opportunities to propel its pipeline toward regulatory milestones.View Anavex Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Peloton Stock Gives Back Gains After Upbeat Earnings ReportDatavalut Gains Traction: 5 Reasons to Sell NowTMC Stock: Why This Pre-Revenue Miner Is Worth WatchingViking Sails to All-Time Highs—Fundamentals Signal More to ComeYETI Rallies After Earnings Beat and Raised OutlookAeluma's Post-Earnings Dip Creates a Buying OpportunityCisco’s Vertical Rally May Still Be in the Early Innings Upcoming Earnings Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026)TJX Companies (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
